Changes in serum prostate-specific antigen levels after potassium-titanyl-phosphate (KTP) laser vaporization of the prostate

Korean Journal of Urology

Volumn 51, Issue 2, 2010, Pages 111-114

  Shim, Myungsun ^a   Kwon, Taekmin ^a   Kim, Seong Chul ^a   Ha, Seong Heon ^a   Ahn, Tai Young ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Potassium titanyl phosphate; Prostate specific antigen; Prostatic hyperplasia

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; HUMAN; LASER; MAJOR CLINICAL STUDY; POTASSIUM TITANYL PHOSPHATE LASER VAPORIZATION; PREOPERATIVE EVALUATION; PROSTATE; PROSTATE HYPERTROPHY; VAPORIZATION;

EID: 77149135248     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2010.51.2.111     Document Type: Article

References (21)

1. Partin AW, Oesterling JE. The clinical usefulness of prostate-specific antigen: update 1994. J Urol 1994;152:1358-68.
2. Oesterling JE, Rice DC, Glenski WJ, Bergstralh EJ. Effect of cystoscopy, prostate biopsy, and transurethral resection of prostate on serum prostate-specific antigen concentration. Urology 1993; 42:276-82.
3. Sershon PD, Barry MJ, Oesterling JE. Serum prostate-specific antigen discriminates weakly between men with benign prostatic hyperplasia and patients with organ-confined prostate cancer. Eur Urol 1994;25:281-7.
4. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004;172:1297-301.
5. Bostwick DG, Cooner WH, Denis L, Jones GW, Scardino PT, Murphy GP. The association of benign prostatic hyperplasia and cancer of the prostate. Cancer 1992;70(1 Suppl):291-301.
6. Marks LS, Dorey FJ, Rhodes T, Shery ED, Rittenhouse H, Partin AW, et al. Serum prostate specific antigen levels after transurethral resection of prostate: a longitudinal characterization in men with benign prostatic hyperplasia. J Urol 1996;156:1035-9.
7. Choo SH, Han DH, Lee SW. The efficacy and safety of KTP photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia: the 2-year results. Korean J Urol 2008; 49:831-6.
8. Bouchier-Hayes DM, Anderson P, Van Appledorn S, Bugeja P, Costello AJ. KTP laser versus transurethral resection: early results of a randomized trial. J Endourol 2006;20:580-5.
9. Hwang EC, Joo JS, Min KD, Oh BR, Kang TW, Kwon DD, et al. A short-term comparative study on efficacy and safety of standard transurethral resection and high power (80W) potassium-titanyl-phosphate laser vaporization of the prostate. Korean J Urol 2005;46:1251-5.
10. Lu-Yao GL, Barry MJ, Chang CH, Wasson JH, Wennberg JE. Transurethral resection of the prostate among medicare beneficiaries in the United States: time trends and outcomes. Prostate Patient Outcomes Research Team (PORT). Urology 1994;44: 692-8.
11. Gu F. Epidemiological survey of benign prostatic hyperplasia and prostatic cancer in China. Chin Med J 2000;113:299-302.
12. Malek RS, Kuntzman RS, Barrett DM. Photoselective potassium-titanyl- phosphate laser vaporization of the benign obstructive prostate: observations on long-term outcomes. J Urol 2005;174:1344-8.
13. Tasci AI, Tugcu V, Sahin S, Zorluoglu F. Rapid communication: photoselective vaporization of the prostate versus transurethral resection of the prostate for the large prostate: a prospective nonrandomized bicenter trial with 2-year follow-up. J Endourol 2008;22:347-53.
14. Ruszat R, Wyler SF, Seitz M, Lehmann K, Abe C, Bonkat G, et al. Comparison of potassium-titanyl-phosphate laser vaporization of the prostate and transurethral resection of the prostate: update of a prospective non-randomized two-centre study. BJU Int 2008;102:1432-8.
15. Horasanli K, Silay MS, Altay B, Tanriverdi O, Sarica K, Miroglu C. Photoselective potassium titanyl phosphate (KTP) laser vaporization versus transurethral resection of the prostate for prostates larger than 70 mL: a short-term prospective randomized trial. Urology 2008;71:247-51.
16. Schwartz I, Wein AJ, Malloy TR, Glick JH. Prostatic cancer after prostatectomy for benign disease. Cancer 1986;58:994-6.
17. Oesterling JE, Tekchandani AH, Martin SK, Bergstralh EJ, Reichstein E, Diamandis EP, et al. The periurethral glands do not significantly influence the serum prostate specific antigen concentration. J Urol 1996;155:1658-60.
18. Cetinkaya M, Ulusoy E, Aki T, Kosan M, Kundak C, Aydos MM, et al. Effect of transurethral resection on serum free/total prostate-specific antigen levels in patients with benign prostatic hyperplasia. Urology 1999;53:118-20.
19. Volkan T, Ihsan TA, Yilmaz O, Emin O, Selcuk S, Loray K, et al. Short term outcomes of high power (80 W) potassium-titanylphosphate laser vaporization of the prostate. Eur Urol 2005;48: 608-13.
20. Aus G, Bergdahl S, Frösing R, Lodding P, Pileblad E, Hugosson J. Reference range of prostate-specific antigen after transurethral resection of the prostate. Urology 1996;47:529-31.
21. Wolff JM, Boekels O, Borchers H, Jakse G, Rohde D. Altered prostate specific antigen reference range after transurethral resection of the prostate. Anticancer Res 2000;20:4977-80.